150 related articles for article (PubMed ID: 37663660)
1. CT-based radiomic phenotypes of lung adenocarcinoma: a preliminary comparative analysis with targeted next-generation sequencing.
Liu X; Xu T; Wang S; Chen Y; Jiang C; Xu W; Gong J
Front Med (Lausanne); 2023; 10():1191019. PubMed ID: 37663660
[TBL] [Abstract][Full Text] [Related]
2. CT-based Radiogenomic Analysis of Clinical Stage I Lung Adenocarcinoma with Histopathologic Features and Oncologic Outcomes.
Perez-Johnston R; Araujo-Filho JA; Connolly JG; Caso R; Whiting K; Tan KS; Zhou J; Gibbs P; Rekhtman N; Ginsberg MS; Jones DR
Radiology; 2022 Jun; 303(3):664-672. PubMed ID: 35230187
[TBL] [Abstract][Full Text] [Related]
3. Consensus Clustering Analysis Based on Enhanced-CT Radiomic Features: Esophageal Squamous Cell Carcinoma patients' 3-Year Progression-Free Survival.
Jia J; Liu Z; Wang F; Bai G
Acad Radiol; 2024 Jan; ():. PubMed ID: 38199900
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Identification of
Zhang T; Xu Z; Liu G; Jiang B; de Bock GH; Groen HJM; Vliegenthart R; Xie X
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920322
[TBL] [Abstract][Full Text] [Related]
5. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
6. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
[TBL] [Abstract][Full Text] [Related]
7. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
9. Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects.
Ma JW; Li M
Transl Cancer Res; 2021 Sep; 10(9):4217-4231. PubMed ID: 35116717
[TBL] [Abstract][Full Text] [Related]
10. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
12. Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images.
Shao J; Ma J; Zhang S; Li J; Dai H; Liang S; Yu Y; Li W; Wang C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230746
[TBL] [Abstract][Full Text] [Related]
13. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Liu Y; Wu A; Li X; Wang S; Fang S; Mo Y
Asian J Surg; 2022 Jan; 45(1):367-375. PubMed ID: 34325991
[TBL] [Abstract][Full Text] [Related]
16. EGFR Mutation Status and Subtypes Predicted by CT-Based 3D Radiomic Features in Lung Adenocarcinoma.
Chen Q; Li Y; Cheng Q; Van Valkenburgh J; Sun X; Zheng C; Zhang R; Yuan R
Onco Targets Ther; 2022; 15():597-608. PubMed ID: 35669165
[TBL] [Abstract][Full Text] [Related]
17. Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules.
Shi W; Yang Z; Zhu M; Zou C; Li J; Liang Z; Wang M; Yu H; Yang B; Wang Y; Li C; Wang Z; Zhao W; Chen L
Front Oncol; 2022; 12():986579. PubMed ID: 36176405
[TBL] [Abstract][Full Text] [Related]
18. Predicting programmed death-ligand 1 expression level in non-small cell lung cancer using a combination of peritumoral and intratumoral radiomic features on computed tomography.
Shiinoki T; Fujimoto K; Kawazoe Y; Yuasa Y; Kajima M; Manabe Y; Ono T; Hirano T; Matsunaga K; Tanaka H
Biomed Phys Eng Express; 2022 Feb; 8(2):. PubMed ID: 35051908
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.
Kadara H; Choi M; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Yoo Y; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Wistuba II; Herbst RS
Ann Oncol; 2017 Jan; 28(1):75-82. PubMed ID: 27687306
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
